[Erythropoietin drugs in patients with chronic renal failure at the stage of conservative treatment. Effectiveness and side effects].
OBJECTIVE
To assess activity and safety of erythropoietin (EP) drugs in conservative chronic renal failure (CRF).


METHODS
The antianemic effect of EP drugs, central and cardiac hemodynamics were studied in 28 CRF patients (mean blood creatinine 5.27 mg%) with renal anemia. In addition, arterial pressure was automatically measured within 24 hours and the CRF progression rate was assessed.


RESULTS
Low-dose EP drugs injected subcutaneously rapidly produced antianemic and cardioprotective effects and may improve residual renal function.


CONCLUSIONS
Pathogenetically grounded and safe for patients with conservative CRF is a combination of low-dose subcutaneous EP drugs with hypotensive drugs (calcium antagonists, ACE inhibitors), loop diuretics and low-protein diet.
Alekseeva
T B
TB
Nikolaev
A Iu
AIu
Dasaeva
L A
LA
D000740:Anemia / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D016896:Treatment Outcome
D011994:Recombinant Proteins; D004921:Erythropoietin